Indication

Diffuse Cutaneous Scleroderma

1 clinical trial

1 product

Clinical trial

A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease

Status: Terminated, Estimated PCD: 2024-02-23

Product